{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T23:52:32Z","timestamp":1790553152496,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T00:00:00Z","timestamp":1548028800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1038\/s41440-019-0211-0","type":"journal-article","created":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T02:02:26Z","timestamp":1548036146000},"page":"892-902","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Effect of a novel nonsteroidal selective mineralocorticoid receptor antagonist, esaxerenone (CS-3150), on blood pressure and renal injury in high salt-treated type 2 diabetic mice"],"prefix":"10.1038","volume":"42","author":[{"given":"Abdus Sattar","family":"Bhuiyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazi","family":"Rafiq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Kobara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Masaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,21]]},"reference":[{"key":"211_CR1","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1254\/jphs.10R06FM","volume":"113","author":"A Nishiyama","year":"2010","unstructured":"Nishiyama A, Hasegawa K, Diah S, Hitomi H. New approaches to blockade of the renin-angiotensin-aldosterone system: mineralocorticoid-receptor blockers exert antihypertensive and renoprotective effects independently of the renin-angiotensin system. J Pharmacol Sci. 2010;113:310\u20134.","journal-title":"J Pharmacol Sci"},{"key":"211_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1254\/jphs.08R12FM","volume":"109","author":"A Nishiyama","year":"2009","unstructured":"Nishiyama A, Hitomi H, Rahman A, Kiyomoto H. Drug discovery for overcoming chronic kidney disease (CKD): pharmacological effects of mineralocorticoid-receptor blockers. J Pharmacol Sci. 2009;109:1\u20136.","journal-title":"J Pharmacol Sci"},{"key":"211_CR3","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/hr.2016.137","volume":"40","author":"S Shibata","year":"2017","unstructured":"Shibata S, Ishizawa K, Uchida S. Mineralocorticoid receptor as a therapeutic target in chronic kidney disease and hypertension. Hypertens Res. 2017;40:221\u20135.","journal-title":"Hypertens Res"},{"key":"211_CR4","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/S2213-8587(14)70194-9","volume":"2","author":"K Ando","year":"2014","unstructured":"Ando K, Ohtsu H, Uchida S, Kaname S, Arakawa Y, Fujita T, EVALUATE Study Group. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2:944\u201353.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"211_CR5","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1007\/s10157-015-1106-2","volume":"19","author":"S Kato","year":"2015","unstructured":"Kato S, Maruyama S, Makino H, Wada J, Ogawa D, Uzu T, et al. Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial. Clin Exp Nephrol. 2015;19:1098\u2013106.","journal-title":"Clin Exp Nephrol"},{"key":"211_CR6","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2215\/CJN.07460713","volume":"9","author":"PN Buren Van","year":"2014","unstructured":"Van Buren PN, Adams-Huet B, Nguyen M, Molina C, Toto RD. Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy. Clin J Am Soc Nephrol. 2014;9:295\u2013301.","journal-title":"Clin J Am Soc Nephrol"},{"key":"211_CR7","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1016\/j.clinthera.2015.05.508","volume":"37","author":"J Hou","year":"2015","unstructured":"Hou J, Xiong W, Cao L, Wen X, Li A. Spironolactone add-on for preventing or slowing the progression of diabetic nephropathy: a meta-analysis. Clin Ther. 2015;37:2086\u2013103.","journal-title":"Clin Ther"},{"key":"211_CR8","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ejim.2013.11.007","volume":"25","author":"TA Mavrakanas","year":"2014","unstructured":"Mavrakanas TA, Gariani K, Martin PY. Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review. Eur J Intern Med. 2014;25:173\u20136.","journal-title":"Eur J Intern Med"},{"key":"211_CR9","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1097\/MNH.0000000000000340","volume":"26","author":"FK Dojki","year":"2017","unstructured":"Dojki FK, Bakris G. Nonsteroidal mineralocorticoid antagonists in diabetic kidney disease. Curr Opin Nephrol Hypertens. 2017;26:368\u201374.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"211_CR10","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ejphar.2015.06.015","volume":"761","author":"K Arai","year":"2015","unstructured":"Arai K, Homma T, Morikawa Y, Ubukata N, Tsuruoka H, Aoki K, et al. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist. Eur J Pharmacol. 2015;761:226\u201334.","journal-title":"Eur J Pharmacol"},{"key":"211_CR11","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1080\/00498254.2016.1263766","volume":"47","author":"M Yamada","year":"2017","unstructured":"Yamada M, Takei M, Suzuki E, Takakusa H, Kotsuma M, Washio T, et al. Pharmacokinetics, distribution, and disposition of esaxerenone, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist, in rats and monkeys. Xenobiotica. 2017;47:1090\u2013103.","journal-title":"Xenobiotica"},{"key":"211_CR12","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1111\/bcp.13616","volume":"84","author":"M Kato","year":"2018","unstructured":"Kato M, Furuie H, Shimizu T, Miyazaki A, Kobayashi F, Ishizuka H. Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects. Br J Clin Pharmacol. 2018;84:1821\u20139.","journal-title":"Br J Clin Pharmacol"},{"key":"211_CR13","doi-asserted-by":"publisher","first-page":"e0254","DOI":"10.1097\/MD.0000000000010254","volume":"97","author":"H Pei","year":"2018","unstructured":"Pei H, Wang W, Zhao D, Wang L, Su GH, Zhao Z. The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure: a systematic review and meta-analysis. Med (Baltim). 2018;97:e0254.","journal-title":"Med (Baltim)"},{"key":"211_CR14","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","volume":"34","author":"B Pitt","year":"2013","unstructured":"Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34:2453\u201363.","journal-title":"Eur Heart J"},{"issue":"9","key":"211_CR15","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/jama.2015.10081","volume":"314","author":"George L. Bakris","year":"2015","unstructured":"Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, et al, Mineralocorticoid Receptor Antagonist Tolerability Study\u2013Diabetic Nephropathy (ARTS-DN) Study Group. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA. 2015;314:884\u201394.","journal-title":"JAMA"},{"key":"211_CR16","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jdiacomp.2016.11.021","volume":"31","author":"S Katayama","year":"2017","unstructured":"Katayama S, Yamada D, Nakayama M, Yamada T, Myoishi M, Kato M, ARTS-DN Japan study group. et al. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy. J Diabetes Complicat. 2017;31:758\u201365.","journal-title":"J Diabetes Complicat"},{"key":"211_CR17","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1111\/dom.13393","volume":"20","author":"M Lachaux","year":"2018","unstructured":"Lachaux M, Barrera-Chimal J, Nicol L, R\u00e9my-Jouet I, Renet S, Dumesnil A, et al. Short- and long-term administration of the non-steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome-related cardio-renal dysfunction. Diabetes Obes Metab. 2018;20:2399\u2013407.","journal-title":"Diabetes Obes Metab"},{"key":"211_CR18","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1161\/HYPERTENSIONAHA.116.08526","volume":"69","author":"L Lattenist","year":"2017","unstructured":"Lattenist L, Lechner SM, Messaoudi S, Le Mercier A, El Moghrabi S, Prince S, et al. Nonsteroidal mineralocorticoid receptor antagonist finerenone protects against acute kidney injury-mediated chronic kidney disease: role of oxidative stress. Hypertension. 2017;69:870\u20138.","journal-title":"Hypertension"},{"key":"211_CR19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","volume":"64","author":"P Kolkhof","year":"2014","unstructured":"Kolkhof P, Delbeck M, Kretschmer A, Steinke W, Hartmann E, B\u00e4rfacker L, et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol. 2014;64:69\u201378.","journal-title":"J Cardiovasc Pharmacol"},{"key":"211_CR20","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ejphar.2015.11.028","volume":"769","author":"K Arai","year":"2015","unstructured":"Arai K, Tsuruoka H, Homma T. CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats. Eur J Pharmacol. 2015;769:266\u201373.","journal-title":"Eur J Pharmacol"},{"key":"211_CR21","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1681\/ASN.2009070721","volume":"20","author":"FC Brosius 3rd","year":"2009","unstructured":"Brosius FC 3rd, Alpers CE, Bottinger EP, Breyer MD, Coffman TM, Gurley SB, Animal Models of Diabetic Complications Consortium et al. Mouse models of diabetic nephropathy. J Am Soc Nephrol. 2009;20:2503\u201312.","journal-title":"J Am Soc Nephrol"},{"key":"211_CR22","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nrneph.2017.142","volume":"14","author":"K Azushima","year":"2018","unstructured":"Azushima K, Gurley SB, Coffman TM. Modelling diabetic nephropathy in mice. Nat Rev Nephrol. 2018;14:48\u201356.","journal-title":"Nat Rev Nephrol"},{"key":"211_CR23","doi-asserted-by":"publisher","first-page":"e82082","DOI":"10.1371\/journal.pone.0082082","volume":"8","author":"K Rafiq","year":"2013","unstructured":"Rafiq K, Sherajee SJ, Hitomi H, Nakano D, Kobori H, Ohmori K, et al. Calcium channel blocker enhances beneficial effects of an angiotensin II AT1 receptor blocker against cerebrovascular-renal injury in type 2 diabetic mice. PLoS One. 2013;8:e82082.","journal-title":"PLoS One"},{"key":"211_CR24","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1254\/jphs.12031FP","volume":"119","author":"B Lei","year":"2012","unstructured":"Lei B, Nakano D, Fan YY, Kitada K, Hitomi H, Kobori H, et al. Add-on aliskiren elicits stronger renoprotection than high-dose valsartan in type 2 diabetic KKAy mice that do not respond to low-dose valsartan. J Pharmacol Sci. 2012;119:131\u20138.","journal-title":"J Pharmacol Sci"},{"key":"211_CR25","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1161\/CIRCULATIONAHA.111.064097","volume":"125","author":"K Rafiq","year":"2012","unstructured":"Rafiq K, Noma T, Fujisawa Y, Ishihara Y, Arai Y, Nabi AH, et al. Renal sympathetic denervation suppresses de novo podocyte injury and albuminuria in rats with aortic regurgitation. Circulation. 2012;125:1402\u201313.","journal-title":"Circulation"},{"key":"211_CR26","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41440-017-0008-y","volume":"41","author":"D Yamazaki","year":"2018","unstructured":"Yamazaki D, Hitomi H, Nishiyama A. Hypertension with diabetes mellitus complications. Hypertens Res. 2018;41:147\u201356.","journal-title":"Hypertens Res"},{"key":"211_CR27","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/hr.2017.65","volume":"40","author":"A Nehme","year":"2017","unstructured":"Nehme A, Zibara K. Efficiency and specificity of RAAS inhibitors in cardiovascular diseases: how to achieve better end-organ protection? Hypertens Res. 2017;40:903\u20139.","journal-title":"Hypertens Res"},{"key":"211_CR28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/hr.2016.90","volume":"40","author":"M Dekleva","year":"2017","unstructured":"Dekleva M, Lazic JS, Arandjelovic A, Mazic S. Beneficial and harmful effects of exercise in hypertensive patients: the role of oxidative stress. Hypertens Res. 2017;40:15\u201320.","journal-title":"Hypertens Res"},{"key":"211_CR29","doi-asserted-by":"publisher","first-page":"e41896","DOI":"10.1371\/journal.pone.0041896","volume":"7","author":"K Kitada","year":"2012","unstructured":"Kitada K, Nakano D, Liu Y, Fujisawa Y, Hitomi H, Shibayama Y, et al. Oxidative stress-induced glomerular mineralocorticoid receptor activation limits the benefit of salt reduction in Dahl salt-sensitive rats. PLoS One. 2012;7:e41896.","journal-title":"PLoS One"},{"key":"211_CR30","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1161\/01.HYP.0000118519.66430.22","volume":"43","author":"A Nishiyama","year":"2004","unstructured":"Nishiyama A, Yao L, Nagai Y, Miyata K, Yoshizumi M, Kagami S, et al. Possible contributions of reactive `oxygen species and mitogen-activated protein kinase to renal injury in aldosterone\/salt-induced hypertensive rats. Hypertension. 2004;43:841\u20138.","journal-title":"Hypertension"},{"key":"211_CR31","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.1172\/JCI43124","volume":"121","author":"S Shibata","year":"2011","unstructured":"Shibata S, Mu S, Kawarazaki H, Muraoka K, Ishizawa K, Yoshida S, et al. Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway. J Clin Invest. 2011;121:3233\u201343.","journal-title":"J Clin Invest"},{"key":"211_CR32","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/nm.1879","volume":"14","author":"S Shibata","year":"2008","unstructured":"Shibata S, Nagase M, Yoshida S, Kawarazaki W, Kurihara H, Tanaka H, et al. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med. 2008;14:1370\u20136.","journal-title":"Nat Med"},{"key":"211_CR33","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1097\/HJH.0b013e3283576904","volume":"30","author":"H Kawarazaki","year":"2012","unstructured":"Kawarazaki H, Ando K, Shibata S, Muraoka K, Fujita M, Kawarasaki C, et al. Mineralocorticoid receptor\u2013Rac1 activation and oxidative stress play major roles in salt-induced hypertension and kidney injury in prepubertal rats. J Hypertens. 2012;30:1977\u201385.","journal-title":"J Hypertens"},{"key":"211_CR34","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1172\/JCI200320530","volume":"112","author":"R Kalluri","year":"2003","unstructured":"Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest. 2003;112:1776\u201384.","journal-title":"J Clin Invest"},{"key":"211_CR35","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1681\/ASN.2012111094","volume":"25","author":"LL Huang","year":"2014","unstructured":"Huang LL, Nikolic-Paterson DJ, Han Y, Ozols E, Ma FY, Young MJ, et al. Myeloid mineralocorticoid receptor activation contributes to progressive kidney disease. J Am Soc Nephrol. 2014;25:2231\u201340.","journal-title":"J Am Soc Nephrol"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41440-019-0211-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41440-019-0211-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41440-019-0211-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:20:19Z","timestamp":1684603219000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-019-0211-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,21]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["211"],"URL":"https:\/\/doi.org\/10.1038\/s41440-019-0211-0","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,21]]},"assertion":[{"value":"7 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This was in part a collaborative study with Daiichi-Sankyo Co., Ltd. (to A.N.). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. This study was also supported in part by the Salt Sciences Foundation (to A.N.).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}